<DOC>
	<DOCNO>NCT00637975</DOCNO>
	<brief_summary>The aim study assess tolerability activity oxycodone pregabalin combination treatment oncological neuropathic pain two different strategy .</brief_summary>
	<brief_title>Oxycodone Pregabalin Treatment Oncological Neuropathic Pain</brief_title>
	<detailed_description>Neuropathic pain frequently diagnose complication cancer pain . While opioids mainstay cancer pain management , efficacy neuropathic pain seem less optimal , adjuvant drug , mainly anticonvulsants antidepressant , often combined opioids analgesic regimen patient neuropathic cancer pain . This approach suggest well-established guideline , analgesic benefit safety pregabalin oxycodone combination yet document . The aim study ass activity tolerability addition pregabalin oxycodone treatment patient neuropathic pain due neoplasm .</detailed_description>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<mesh_term>Oxycodone</mesh_term>
	<criteria>instrumental clinical diagnosis every malignant neoplasm presence pain neuropathic component opinion physician presence pain &gt; =4 ( NRS ) PS ECOG &lt; 3 write informed consent serum creatinine &gt; 2mg/ml creatinine clearance &lt; 40 ml/min mild severe hepatic insufficiency iatrogenic neuropathy cause chemotherapeutic agent previous allergic reaction oxycodone pregabalin pregnancy breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>neuropathic pain</keyword>
	<keyword>oxycodone</keyword>
	<keyword>pregabalin</keyword>
	<keyword>Patients cancer present neuropathic pain</keyword>
</DOC>